Dental care for patients taking antiresorptive drugs: a literature review

키워드

참고문헌 (95)

1. Ruggiero SL, "Osteonecrosis of the jaws and bisphosphonate therapy", J Dent Res, 86, pp.1013~1021 (2007)
2. Marx RE, "Pamidronate(Aredia)and zoledronate(Zometa)induced avascular necrosis of the jaws : a growing epidemic", J Oral Maxillofac Surg, 61, pp.1115~1117 (2003)
3. Ruggiero SL, "American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update", J Oral Maxillofac Surg, 72, pp.1938~1956 (2014)
4. Ruggiero SL, "American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update", J Oral Maxillofac Surg, 67, pp.2~12 (2009)
5. Hellstein JW, "Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs", J Am Dent Assoc, 142, pp.1243~1251 (2011)
6. Fleisch H, "Development of bisphosphonates", Breast Cancer Res, 4, pp.30~34 (2002)
7. Letocha AD, "Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement", J Bone Miner Res, 20, pp.977~986 (2005)
8. Delmas PD, "The use of bisphosphonates in the treatment of osteoporosis", Curr Opin Rheumatol, 17, pp.462~466 (2005)
9. Brufsky AM, "Zoledronic acid for cancer therapy--induced and postmenopausal bone loss", Expert Opin Pharmacother, 9, pp.1013~1028 (2008)
10. Berenson JR, "American Society of Clinical Oncology clinical practice guidelines : the role of bisphosphonates in multiple myeloma", J Clin Oncol, 20, pp.3719~3736 (2002)
11. Rosen LS, "Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors : a randomized, Phase III, double-blind, placebo-controlled trial", Cancer, 100, pp.2613~2621 (2004)
12. Russell RG, "Bisphosphonates : from the laboratory to the clinic and back again", Bone, 25, pp.97~106 (1999)
13. Bogado CE, "Denosumab: what's new?", Curr Osteoporos Rep, 9, pp.12~19 (2011)
14. Fleisch H, "Bisphosphonates : mechanisms of action", Endocr Rev, 19, pp.80~100 (1998)
15. Romas E, "Clinical applications of RANK-ligand inhibition", Intern Med J, 39, pp.110~116 (2009)
16. Geusens P, "Emerging treatments for postmenopausal osteoporosis - focus on denosumab", Clin Interv Aging, 4, pp.241~250 (2009)
17. Uyanne J, "Antiresorptive drug-related osteonecrosis of the jaw", Dent Clin North Am, 58, pp.369~384 (2014)
18. Hao L, "A small molecule, odanacatib, inhibits inflammation and bone loss caused by endodontic disease", Infect Immun, 83, pp.1235~1245 (2015)
19. Mullard A, "Merck &Co. drops osteoporosis drug odanacatib", Nat Rev Drug Discov, 15, pp.669~ (2016)
20. Boquete-Castro A, "Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials", Clin Oral Implants Res, 27, pp.367~375 (2016)
21. Yoneda T, "Antiresorptive agent-related osteonecrosis of the jaw : position paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw", J Bone Miner Metab, 35, pp.6~19 (2017)
22. Khan AA, "Case-based review of osteonecrosis of the jaw(ONJ)and application of the international recommendations for management from the International Task Force on ONJ", J Clin Densitom, 20, pp.8~24 (2017)
23. Nicolatou-Galitis O, "Medication-related osteonecrosis of the jaw : definition and best practice for prevention, diagnosis, and treatment", Oral Surg Oral Med Oral Pathol Oral Radiol, 127, pp.117~135 (2019)
24. Khan A, "Osteonecrosis of the jaw(ONJ) : diagnosis and management in 2015", Osteoporos Int, 27, pp.853~859 (2016)
25. Durie BG, "Osteonecrosis of the jaw and bisphosphonates", N Engl J Med, 353, pp.99~102 (2005)
26. Jadu F, "A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients", Ann Oncol, 18, pp.2015~2019 (2007)
27. Saad F, "Incidence, risk factors, and outcomes of osteonecrosis of the jaw : integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases", Ann Oncol, 23, pp.1341~1347 (2012)
28. Vahtsevanos K, "Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw", J Clin Oncol, 27, pp.5356~5362 (2009)
29. Stopeck AT, "Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer : a randomized, double-blind study", J Clin Oncol, 28, pp.5132~5139 (2010)
30. Stopeck AT, "Safety of long-term denosumab therapy : results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer", Support Care Cancer, 24, pp.447~455 (2016)
31. Fedele S, "Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw : a case series", Am J Med, 123, pp.1060~1064 (2010)
32. Lodi G, "Tooth extraction in patients taking intravenous bisphosphonates : a preventive protocol and case series", J Oral Maxillofac Surg, 68, pp.107~110 (2010)
33. Mozzati M, "Tooth extraction in patients on zoledronic acid therapy", Oral Oncol, 48, pp.817~821 (2012)
34. Mavrokokki T, "Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia", J Oral Maxillofac Surg, 65, pp.415~423 (2007)
35. Otto S, "Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: a trigger for BRONJ development?", J Craniomaxillofac Surg, 43, pp.847~854 (2015)
36. Otto S, "Bisphosphonate-related osteonecrosis of the jaw: is pH the missing part in the pathogenesis puzzle?", J Oral Maxillofac Surg, 68, pp.1158~1161 (2010)
37. Otto S, "Osteonecrosis of the jaw : effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism", J Oral Maxillofac Surg, 68, pp.2837~2845 (2010)
38. Aguirre JI, "Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats(Oryzomys palustris)with periodontitis", J Bone Miner Res, 27, pp.2130~2143 (2012)
39. Song M, "Preexisting periapical inflammatory condition exacerbates tooth extraction–induced bisphosphonate-related osteonecrosis of the jaw lesions in mice", J Endod, 42, pp.1641~1646 (2016)
40. Kim T, "Removal of pre-existing periodontal inflammatory condition before tooth extraction ameliorates medication-related osteonecrosis of the jaw-like lesion in mice", Am J Pathol, 188, pp.2318~2327 (2018)
41. Ramírez L, "New non-bisphosphonate drugs that produce osteonecrosis of the jaws", Oral Health Prev Dent, 13, pp.385~393 (2015)
42. Khan AA, "Diagnosis and management of osteonecrosis of the jaw : a systematic review and international consensus", J Bone Miner Res, 30, pp.3~23 (2015)
43. Rosella D, "Medication-related osteonecrosis of the jaw : clinical and practical guidelines", J Int Soc Prev Community Dent, 6, pp.97~104 (2016)
44. Karna H, "Risk-reductive dental strategies for medication related osteonecrosis of the jaw among cancer patients : a systematic review with meta-analyses", Oral Oncol, 85, pp.15~23 (2018)
45. Dimopoulos MA, "Reduction of osteonecrosis of the jaw(ONJ)after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid", Ann Oncol, 20, pp.117~120 (2009)
46. Mücke T, "Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid-A prospective study over 6 years", J Craniomaxillofac Surg, 44, pp.1689~1693 (2016)
47. Vandone AM, "Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw : a single-center clinical experience", Ann Oncol, 23, pp.193~200 (2012)
48. Bramati A, "Prospective, mono-institutional study of the impact of a systematic prevention program on incidence and outcome of osteonecrosis of the jaw in patients treated with bisphosphonates for bone metastases", J Bone Miner Metab, 33, pp.119~124 (2015)
49. Campisi G, "Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents", Future Oncol, 10, pp.257~275 (2014)
50. Marx RE, "Oral bisphosphonate-induced osteonecrosis : risk factors, prediction of risk using serum CTX testing, prevention, and treatment", J Oral Maxillofac Surg, 65, pp.2397~2410 (2007)
51. Chiu WY, "The risk of osteonecrosis of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene", J Clin Endocrinol Metab, 99, pp.2729~2735 (2014)
52. Barasch A, "Risk factors for osteonecrosis of the jaws : a case-control study from the CONDOR dental PBRN", J Dent Res, 90, pp.439~444 (2011)
53. Coleman R, "Bone health in cancer patients: ESMO clinical practice guidelines", Ann Oncol, 25(Supplement 3), pp.iii124~iii137 (2014)
54. McCloskey EV, "Access to fracture risk assessment by FRAX and linked National Osteoporosis Guideline Group(NOGG)guidance in the UK-an analysis of anonymous website activity", Osteoporos Int, 28, pp.71~76 (2017)
55. Fedele S, "Dental management of patients at risk of osteochemonecrosis of the jaws : a critical review", Oral Dis, 15, pp.527~537 (2009)
56. Kim I, "The effect of systemically administered bisphosphonates on bony healing after tooth extraction and osseointegration of dental implants in the rabbit maxilla", Int J Oral Maxillofac Implants, 28, pp.1194~1200 (2013)
57. Dhesy-Thind S, "Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer : a Cancer Care Ontario and American Society of Clinical Oncology clinical practice guideline", J Clin Oncol, 35, pp.2062~2081 (2017)
58. Stockmann P, "Panoramic radiograph, computed tomography or magnetic resonance imaging. Which imaging technique should be preferred in bisphosphonate-associated osteonecrosis of the jaw? A prospective clinical study", Clin Oral Investig, 14, pp.311~317 (2010)
59. Bianchi SD, "Computerized tomographic findings in bisphosphonate-associated osteonecrosis of the jaw in patients with cancer", Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 104, pp.249~258 (2007)
60. Kang B, "Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice", J Bone Miner Res, 28, pp.1631~1640 (2013)
61. Ferraz CC, "Apical extrusion of debris and irrigants using two hand and three engine-driven instrumentation techniques", Int Endod J, 34, pp.354~358 (2001)
62. Gallego L, "Rubber dam clamp trauma during endodontic treatment : a risk factor of bisphosphonate-related osteonecrosis of the jaw", J Oral Maxillofac Surg, 69, pp.e93~e95 (2011)
63. Moinzadeh AT, "Bisphosphonates and their clinical implications in endodontic therapy", Int Endod J, 46, pp.391~398 (2013)
64. AlRahabi MK, "Clinical impact of bisphosphonates in root canal therapy", Saudi Med J, 39, pp.232~238 (2018)
65. Marx RE, "Bisphosphonate-induced exposed bone(osteonecrosis", osteopetrosis)of the jaws : risk factors, recognition, prevention, and treatment, 2005, pp.63, 1567~1575
66. Poubel VL, "The risk of osteonecrosis on alveolar healing after tooth extraction and systemic administration of antiresorptive drugs in rodents : a systematic review", J Craniomaxillofac Surg, 46, pp.245~256 (2018)
67. Borromeo GL, "A review of the clinical implications of bisphosphonates in dentistry", Aust Dent J, 56, pp.2~9 (2011)
68. Saia G, "Occurrence of bisphosphonate-related osteonecrosis of the jaw after surgical tooth extraction", J Oral Maxillofac Surg, 68, pp.797~804 (2010)
69. Kwon YD, "Retrospective study of two biochemical markers for the risk assessment of oral bisphosphonate-related osteonecrosis of the jaws : can they be utilized as risk markers", Clin Oral Implants Res, 22, pp.100~105 (2011)
70. Lee CY, "CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part II: a prospective clinical study", Implant Dent, 19, pp.29~38 (2010)
71. Kunchur R, "Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws", J Oral Maxillofac Surg, 67, pp.1167~1173 (2009)
72. O'Connell JE, "A role for C-terminal cross-linking telopeptide (CTX) level to predict the development of bisphosphonate-related osteonecrosis of the jaws (BRONJ) following oral surgery?", Ir J Med Sci, 181, pp.237~242 (2012)
73. 김경민, "Medication Related Osteonecrosis of the Jaw: 2015 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons", 대한골대사학회지, 22(4), pp.151~165 (2015), 대한골대사학회
74. Hasegawa T, "A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ?", Osteoporos Int, 28, pp.2465~2473 (2017)
75. de Molon RS, "OPG-Fc but not zoledronic acid discontinuation reverses osteonecrosis of the jaws(ONJ)in mice", J Bone Miner Res, 30, pp.1627~1640 (2015)
76. Ohga N, "Healing of osteonecrosis of the jaw(ONJ)after discontinuation of denosumab in a patient with bone metastases of colorectal cancer : a case report and hypothesis", Quintessence Int, 46, pp.621~626 (2015)
77. Yamazaki T, "Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates : a cohort study", Int J Oral Maxillofac Surg, 41, pp.1397~1403 (2012)
78. Tsao C, "Oral health risk factors for bisphosphonate-associated jaw osteonecrosis", J Oral Maxillofac Surg, 71, pp.1360~1366 (2013)
79. Allen MR, "Medication-related osteonecrosis of the jaw : basic and translational science updates", Oral Maxillofac Surg Clin North Am, 27, pp.497~508 (2015)
80. Hikita H, "Bisphosphonate administration prior to tooth extraction delays initial healing of the extraction socket in rats", J Bone Miner Metab, 27, pp.663~672 (2009)
81. Landesberg R, "Potential pathophysiological mechanisms in osteonecrosis of the jaw", Ann N Y Acad Sci, 1218, pp.62~79 (2011)
82. Ravosa MJ, "Bisphosphonate effects on the behaviour of oral epithelial cells and oral fibroblasts", Arch Oral Biol, 56, pp.491~498 (2011)
83. Pabst AM, "The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes--in vitro study", Clin Oral Investig, 16, pp.87~93 (2012)
84. Yamashita J, "Effect of zoledronate on oral wound healing in rats", Clin Cancer Res, 17, pp.1405~1414 (2011)
85. Allam E, "In vivo effects of zoledronic acid on oral mucosal epithelial cells", Oral Dis, 17, pp.291~297 (2011)
86. Iwamatsu-Kobayashi Y, "A case of multiple idiopathic external root resorption : a 6-year follow-up study", Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 100, pp.772~779 (2005)
87. Patel S, "External cervical resorption associated with the use of bisphosphonates : a case series", J Endod, 41, pp.742~748 (2015)
88. Hewitt RE, "The bisphosphonate acute phase response : rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins", Clin Exp Immunol, 139, pp.101~111 (2005)
89. Makkonen N, "Contrasting effects of alendronate and clodronate on RAW 264 macrophages : the role of a bisphosphonate metabolite", Eur J Pharm Sci, 8, pp.109~118 (1999)
90. Dicuonzo G, "Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6", J Interferon Cytokine Res, 23, pp.649~654 (2003)
91. Deeb JG, "Discontinuation of denosumab as a potential cause of generalized external cervical root resorption : a case report", J Endod, 45, pp.640~644 (2019)
92. Eastell R, "Effects of denosumab on bone turnover markers in postmenopausal osteoporosis", J Bone Miner Res, 26, pp.530~537 (2011)
93. Hsiao A, "A retrospective clinical and radiographic study on healing of periradicular lesions in patients taking oral bisphosphonates", J Endod, 35, pp.1525~1528 (2009)
94. Dereci Ö, "The effect of the duration of intravenous zolendronate medication on the success of non-surgical endodontic therapy : a retrospective study", BMC Oral Health, 16, pp.9~ (2016)
95. Knight RJ, "Bisphosphonate-related osteonecrosis of the jaw : tip of the iceberg", J Craniofac Surg, 21, pp.25~32 (2010)

관련 논문AI추천